Format

Send to

Choose Destination
Cell Stem Cell. 2010 Jun 4;6(6):517-20. doi: 10.1016/j.stem.2010.05.012.

Pharma's developing interest in stem cells.

Author information

1
Pfizer Regenerative Medicine, Cambridge, UK. ruth.mckernan@pfizer.com

Abstract

Human stem cell biology is driving the promise of novel regenerative therapies into clinical trials. Although the pharmaceutical industry has embraced stem cells as tools in drug discovery, few companies have taken the risk to deliver stem cell-based medicines. Here, we evaluate the various cell-based opportunities and corporate strategies.

PMID:
20569688
DOI:
10.1016/j.stem.2010.05.012
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center